IBDEI1FD ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25271,0)
 ;;=V58.65^^144^1577^26
 ;;^UTILITY(U,$J,358.3,25271,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25271,1,2,0)
 ;;=2^V58.65
 ;;^UTILITY(U,$J,358.3,25271,1,5,0)
 ;;=5^LONG-TERM USE STEROIDS
 ;;^UTILITY(U,$J,358.3,25271,2)
 ;;=^329980
 ;;^UTILITY(U,$J,358.3,25272,0)
 ;;=V58.66^^144^1577^24
 ;;^UTILITY(U,$J,358.3,25272,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25272,1,2,0)
 ;;=2^V58.66
 ;;^UTILITY(U,$J,358.3,25272,1,5,0)
 ;;=5^LONG-TERM USE OF ASPIRIN
 ;;^UTILITY(U,$J,358.3,25272,2)
 ;;=^331584
 ;;^UTILITY(U,$J,358.3,25273,0)
 ;;=V58.67^^144^1577^25
 ;;^UTILITY(U,$J,358.3,25273,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25273,1,2,0)
 ;;=2^V58.67
 ;;^UTILITY(U,$J,358.3,25273,1,5,0)
 ;;=5^LONG-TERM USE OF INSULIN
 ;;^UTILITY(U,$J,358.3,25273,2)
 ;;=^331585
 ;;^UTILITY(U,$J,358.3,25274,0)
 ;;=V58.69^^144^1577^19
 ;;^UTILITY(U,$J,358.3,25274,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25274,1,2,0)
 ;;=2^V58.69
 ;;^UTILITY(U,$J,358.3,25274,1,5,0)
 ;;=5^L/T (CURRENT) USE - OTH MEDS
 ;;^UTILITY(U,$J,358.3,25274,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,25275,0)
 ;;=V65.40^^144^1577^30
 ;;^UTILITY(U,$J,358.3,25275,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25275,1,2,0)
 ;;=2^V65.40
 ;;^UTILITY(U,$J,358.3,25275,1,5,0)
 ;;=5^OTH UNSP COUNSEL NOC
 ;;^UTILITY(U,$J,358.3,25275,2)
 ;;=^87449
 ;;^UTILITY(U,$J,358.3,25276,0)
 ;;=V65.41^^144^1577^10
 ;;^UTILITY(U,$J,358.3,25276,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25276,1,2,0)
 ;;=2^V65.41
 ;;^UTILITY(U,$J,358.3,25276,1,5,0)
 ;;=5^EXERCISE COUNSELING
 ;;^UTILITY(U,$J,358.3,25276,2)
 ;;=^303466
 ;;^UTILITY(U,$J,358.3,25277,0)
 ;;=V65.43^^144^1577^4
 ;;^UTILITY(U,$J,358.3,25277,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25277,1,2,0)
 ;;=2^V65.43
 ;;^UTILITY(U,$J,358.3,25277,1,5,0)
 ;;=5^COUNSEL-INJURY PREVEN
 ;;^UTILITY(U,$J,358.3,25277,2)
 ;;=^303468
 ;;^UTILITY(U,$J,358.3,25278,0)
 ;;=V65.45^^144^1577^5
 ;;^UTILITY(U,$J,358.3,25278,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25278,1,2,0)
 ;;=2^V65.45
 ;;^UTILITY(U,$J,358.3,25278,1,5,0)
 ;;=5^COUNSEL-OTH SEX TX DISEASES
 ;;^UTILITY(U,$J,358.3,25278,2)
 ;;=^303470
 ;;^UTILITY(U,$J,358.3,25279,0)
 ;;=V68.89^^144^1577^9
 ;;^UTILITY(U,$J,358.3,25279,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25279,1,2,0)
 ;;=2^V68.89
 ;;^UTILITY(U,$J,358.3,25279,1,5,0)
 ;;=5^EQUIP SET/ORIENT/ADJUST
 ;;^UTILITY(U,$J,358.3,25279,2)
 ;;=^295588
 ;;^UTILITY(U,$J,358.3,25280,0)
 ;;=V71.09^^144^1578^1
 ;;^UTILITY(U,$J,358.3,25280,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25280,1,2,0)
 ;;=2^V71.09
 ;;^UTILITY(U,$J,358.3,25280,1,5,0)
 ;;=5^OBSERV-MENTAL COND NEC
 ;;^UTILITY(U,$J,358.3,25280,2)
 ;;=^295604
 ;;^UTILITY(U,$J,358.3,25281,0)
 ;;=99080^^145^1579^7^^^^1
 ;;^UTILITY(U,$J,358.3,25281,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,25281,1,2,0)
 ;;=2^99080
 ;;^UTILITY(U,$J,358.3,25281,1,3,0)
 ;;=3^SPECIAL REPORTS OR FORMS
 ;;^UTILITY(U,$J,358.3,25282,0)
 ;;=97535^^145^1579^6^^^^1
 ;;^UTILITY(U,$J,358.3,25282,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,25282,1,2,0)
 ;;=2^97535
 ;;^UTILITY(U,$J,358.3,25282,1,3,0)
 ;;=3^SELF CARE MNGMENT TRAINING
 ;;^UTILITY(U,$J,358.3,25283,0)
 ;;=99366^^145^1579^8^^^^1
 ;;^UTILITY(U,$J,358.3,25283,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,25283,1,2,0)
 ;;=2^99366
 ;;^UTILITY(U,$J,358.3,25283,1,3,0)
 ;;=3^TEAM CONF W/PAT BY HC PRO
 ;;^UTILITY(U,$J,358.3,25284,0)
 ;;=A9279^^145^1579^5^^^^1
 ;;^UTILITY(U,$J,358.3,25284,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,25284,1,2,0)
 ;;=2^A9279
 ;;^UTILITY(U,$J,358.3,25284,1,3,0)
 ;;=3^MONITORING FEATURE/DEVICE NOC
 ;;
 ;;$END ROU IBDEI1FD
